BioCentury | Apr 18, 2019
Distillery Therapeutics

Plasmid-encoded toxin for targeted killing of antibiotic-resistant bacteria

DISEASE CATEGORY: Infectious disease INDICATION: Cholera; Gram-negative bacterial infection Cell culture, zebrafish and brine shrimp studies suggest a toxin-encoding plasmid could help treat infection by antibiotic-resistant Vibrio cholerae and other antibiotic-resistant Gram-negative bacteria. The plasmid...
BioCentury | Jan 28, 2019
Preclinical News

Unfolded protein response activates MYC in prostate cancer

A European team has linked the unfolded protein response to MYC signaling, lending weight to oncology strategies targeting the IRE1/XBP1 pathway, and identified prostate cancer as another indication for XBP1 inhibitors. A U.S. team including...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...
BioCentury | Nov 15, 2018
Product R&D

Tempest takes PPAR alpha into cancer

Tempest Therapeutics Inc.’s first data from its preclinical PPARα program gave it the support it was looking for to repurpose the cardiovascular target for cancer. Tapping into the emerging field of cancer immuno-metabolism, Tempest is...
BioCentury | Oct 10, 2018
Preclinical News

Quentis links ER stress, mitochondrial dysfunction with antitumor T cell activity

Researchers at Quentis Therapeutics Inc. (New York, N.Y.), Weill Cornell Medicine and Dana-Farber Cancer Institute uncovered a new mechanism of tumor immune evasion in which endoplasmic reticulum stress limits mitochondrial respiration and antitumor activity in...
BioCentury | Apr 13, 2018
Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
BioCentury | Feb 27, 2018
Emerging Company Profile

Stressing out cancer

Quentis Therapeutics Inc. debuted with a $48 million series A round to develop potentially first-in-class therapies that inhibit the ER stress response, with the dual effect of killing tumor cells directly and unleashing immune cells...
BioCentury | Jan 17, 2018
Distillery Therapeutics


...INDICATION: Huntington's disease (HD) Cell culture studies suggest promoting the expression of ATF4 and CTH could...
...conditions, a tool compound that promotes stress in the Golgi apparatus (monensin) increased levels of ATF4...
...promoters of ATF4 and CTH expression in animal models of HD. TARGET/MARKER/PATHWAY: Cystathionine γ-lyase (CTH); activating transcription factor 4 (ATF4)...
BioCentury | Nov 1, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: October 2017

New Therapeutic Targets and Biomarkers: October 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during October 2017. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Oct 19, 2017

Broad umbrella

In its $50 million tie-up with the Broad Institute of MIT and Harvard , Deerfield Management is looking to forge a new mold of partnership with an academic organization that allows it to efficiently survey early...
Items per page:
1 - 10 of 42